Protective role of V-set and immunoglobulin domain-containing 4 expressed on kupffer cells during immune-mediated liver injury by inducing tolerance of liver T- and natural killer T-cells - PubMed (original) (raw)
. 2012 Nov;56(5):1838-48.
doi: 10.1002/hep.25906.
Affiliations
- PMID: 22711680
- DOI: 10.1002/hep.25906
Protective role of V-set and immunoglobulin domain-containing 4 expressed on kupffer cells during immune-mediated liver injury by inducing tolerance of liver T- and natural killer T-cells
Keunok Jung et al. Hepatology. 2012 Nov.
Abstract
V-set and Ig domain-containing 4 (VSIG4, CRIg, or Z39Ig), a newly identified B7-related cosignaling molecule, is a complement receptor and a coinhibitory ligand that negatively regulates T-cell immunity. Despite its exclusive expression on liver Kupffer cells (KCs) that play key roles in liver tolerance, the physiological role of VSIG4 in liver tolerance remains undefined. Mice lacking VSIG4 had poor survival rates and severe liver pathology in a concanavalin A (ConA)-induced hepatitis (CIH) model, which could be prevented by adoptive transfer of VSIG4(+) KCs. The absence of VSIG4 rendered endogenous liver T- and natural killer T (NKT)-cells more responsive to antigen-specific stimulation and impaired tolerance induction in those cells against their cognate antigens. T-cell costimulation with VSIG4.Ig suppressed Th1-, Th2-, and Th17-type cytokine production and arrested the cell cycle at the G(0) /G(1) phase but did not induce apoptosis in vitro. VSIG4-mediated tolerance induction and cell-cycle arrest were further supported by down-regulation of G(1) phase-specific Cdk2, Cdk4, and Cdk6, and up-regulation of tolerance-inducing p27(KIP-1) in VSIG4.Ig-stimulated T-cells. Administration of soluble VSIG4.Ig to wildtype mice prevented CIH development and prolonged the survival of mice with established CIH.
Conclusion: Collectively, our results suggest that VSIG4(+) KCs play a critical role in the induction and maintenance of liver T- and NKT-cell tolerance, and that modulation of the VSIG4 pathway using a VSIG4.Ig fusion protein may provide useful immunological therapies against immune-mediated liver injury including autoimmune hepatitis.
Copyright © 2012 American Association for the Study of Liver Diseases.
Similar articles
- V-set and Ig domain-containing 4 (VSIG4)-expressing hepatic F4/80+ cells regulate oral antigen-specific responses in mouse.
Shin W, Jeon Y, Choi I, Kim YJ. Shin W, et al. Eur J Immunol. 2018 Apr;48(4):632-643. doi: 10.1002/eji.201747212. Epub 2018 Jan 18. Eur J Immunol. 2018. PMID: 29235119 - Monitoring liver macrophages using nanobodies targeting Vsig4: concanavalin A induced acute hepatitis as paradigm.
Zheng F, Devoogdt N, Sparkes A, Morias Y, Abels C, Stijlemans B, Lahoutte T, Muyldermans S, De Baetselier P, Schoonooghe S, Beschin A, Raes G. Zheng F, et al. Immunobiology. 2015 Feb;220(2):200-9. doi: 10.1016/j.imbio.2014.09.018. Epub 2014 Oct 2. Immunobiology. 2015. PMID: 25440182 - VISTA Stimulation of VSIG4-Positive Macrophages Strongly Suppresses T Cell Proliferation via Excessive Nitric Oxide Production in Sepsis.
Lee SW. Lee SW. Biol Pharm Bull. 2021 Nov 1;44(11):1645-1652. doi: 10.1248/bpb.b21-00616. Epub 2021 Aug 26. Biol Pharm Bull. 2021. PMID: 34433706 - Tolerance induction in response to liver inflammation.
Erhardt A, Tiegs G. Erhardt A, et al. Dig Dis. 2010;28(1):86-92. doi: 10.1159/000282069. Epub 2010 May 7. Dig Dis. 2010. PMID: 20460895 Review. - A role of macrophage complement receptor CRIg in immune clearance and inflammation.
He JQ, Wiesmann C, van Lookeren Campagne M. He JQ, et al. Mol Immunol. 2008 Oct;45(16):4041-7. doi: 10.1016/j.molimm.2008.07.011. Epub 2008 Aug 26. Mol Immunol. 2008. PMID: 18752851 Review.
Cited by
- Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance.
Roohani S, Tacke F. Roohani S, et al. Int J Mol Sci. 2021 Jul 6;22(14):7249. doi: 10.3390/ijms22147249. Int J Mol Sci. 2021. PMID: 34298870 Free PMC article. Review. - A rat liver cell atlas reveals intrahepatic myeloid heterogeneity.
Pouyabahar D, Chung SW, Pezzutti OI, Perciani CT, Wang X, Ma XZ, Jiang C, Camat D, Chung T, Sekhon M, Manuel J, Chen XC, McGilvray ID, MacParland SA, Bader GD. Pouyabahar D, et al. iScience. 2023 Oct 14;26(11):108213. doi: 10.1016/j.isci.2023.108213. eCollection 2023 Nov 17. iScience. 2023. PMID: 38026201 Free PMC article. - Construction and validation of a prognostic nine-gene signature associated with radiosensitivity in head and neck squamous cell carcinoma.
Lu C, Sun Q, Guo Y, Han X, Zhang M, Liu J, Wang Y, Mou Y, Li Y, Song X. Lu C, et al. Clin Transl Radiat Oncol. 2023 Oct 2;43:100686. doi: 10.1016/j.ctro.2023.100686. eCollection 2023 Nov. Clin Transl Radiat Oncol. 2023. PMID: 37854672 Free PMC article. - Identification of Signature Genes of Dilated Cardiomyopathy Using Integrated Bioinformatics Analysis.
Wu Z, Wang X, Liang H, Liu F, Li Y, Zhang H, Wang C, Wang Q. Wu Z, et al. Int J Mol Sci. 2023 Apr 16;24(8):7339. doi: 10.3390/ijms24087339. Int J Mol Sci. 2023. PMID: 37108502 Free PMC article. - The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.
Roh J, Jeon Y, Lee AN, Lee SM, Kim Y, Sung CO, Park CJ, Hong JY, Yoon DH, Suh C, Huh J, Choi I, Park CS. Roh J, et al. Oncotarget. 2017 Jul 22;8(35):58122-58132. doi: 10.18632/oncotarget.19468. eCollection 2017 Aug 29. Oncotarget. 2017. PMID: 28938542 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical